Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 9 (September)

1. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells.
   FASEB J, 21(11): 2725-34. [Abstract] [Full-text]
2. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
   J Neurochem, 102(6): 1749-57. [Abstract] [Full-text]
3. Lipid rafts are required for Kit survival and proliferation signals.
   Blood, 110(6): 1739-47. [Abstract] [Full-text]
4. Farnesyl transferase inhibitor resistance probed by target mutagenesis.
   Blood, 110(6): 2102-9. [Abstract] [Full-text]
5. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
   J Clin Invest, 117(9): 2408-21. [Abstract] [Full-text]
6. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
   J Clin Invest, 117(9): 2562-9. [Abstract] [Full-text]
7. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
   Leuk Lymphoma, 48(9): 1858-65. [Abstract] [Full-text]
8. Management of gastrointestinal stromal tumours: a single-centre experience.
   Ir J Med Sci, 176(3): 157-60. [Abstract] [Full-text]
9. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
   J Thorac Oncol, 2(9): 854-61. [Abstract] [Full-text]
10. Safety of Imatinib in Chronic Myeloid Leukemia in Blastic Crisis Presenting as Cholestatic Jaundice.
    Acta Haematol, 118(3): 141-145. [Abstract] [Full-text]
11. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Cancer Res, 67(17): 7987-90. [Abstract] [Full-text]
12. A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab, 92(9): 3466-9. [Abstract] [Full-text]
13. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cancer, 110(6): 1295-302. [Abstract] [Full-text]
14. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Hematol Oncol, 25(3): 143-7. [Abstract] [Full-text]
15. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
    Gene, 401(1): 38-45. [Abstract] [Full-text]
16. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Cancer, 110(6): 1178-86. [Abstract] [Full-text]
17. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
    Nat Biotechnol, 25(9): 1035-44. [Abstract] [Full-text]
18. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
    Br J Cancer, 97(6): 735-40. [Abstract] [Full-text]
19. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
    Exp Lung Res, 33(7): 357-73. [Abstract] [Full-text]
20. Hypereosinophilic syndromes.
    Orphanet J Rare Dis, 2(1): 37. [Abstract] [Full-text]
21. Gastrointestinal stromal tumors (GIST) and laparoscopic resection.
    Surg Endosc, 21(10): 1685-9. [Abstract] [Full-text]
22. Beyond genomics.
    Clin Pharmacol Ther, 82(4): 366-70. [Abstract] [Full-text]
23. Aggressive systemic mastocytosis presenting with hepatic cholestasis.
    Eur J Gastroenterol Hepatol, 19(10): 901-5. [Abstract] [Full-text]
24. Loeffler endocarditis: what have we learned?
    Am J Hematol, 82(10): 861-2. [Abstract] [Full-text]
25. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors.
    Lab Invest, 87(10): 1029-41. [Abstract] [Full-text]
26. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
    Genes Dev, 21(18): 2283-7. [Abstract] [Full-text]
27. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells.
    Angiogenesis. [Abstract] [Full-text]
28. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Clin Cancer Res, 13(18): 5398-405. [Abstract] [Full-text]
29. Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantation.
    Am J Clin Pathol, 128(4): 565-70. [Abstract] [Full-text]
30. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.
    Leukemia, 21(10): 2094-102. [Abstract] [Full-text]
31. Dermatofibrosarcoma protuberans: recent clinical progress.
    Ann Surg Oncol, 14(10): 2876-86. [Abstract] [Full-text]
32. Leukemia stem cells in a genetically defined murine model of blast-crisis CML.
    Blood, 110(7): 2578-85. [Abstract] [Full-text]
33. The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
    Blood, 110(7): 2556-60. [Abstract] [Full-text]
34. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
    Blood, 110(7): 2309-15. [Abstract] [Full-text]
35. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
    Blood, 110(7): 2242-9. [Abstract] [Full-text]
36. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
    Cancer, 110(5): 955-64. [Abstract] [Full-text]
37. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
    Eur J Surg Oncol, 33(8): 942-50. [Abstract] [Full-text]
38. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
    Eur J Surg Oncol, 33(8): 1030-5. [Abstract] [Full-text]
39. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Exp Hematol, 35(10): 1510-21. [Abstract] [Full-text]
40. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
    Eur J Clin Invest, 37(10): 808-13. [Abstract] [Full-text]
41. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Am J Ther, 14(5): 484-7. [Abstract] [Full-text]
42. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Cancer, 110(7): 1509-19. [Abstract] [Full-text]
43. Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors.
    Cancer Sci, 98(11): 1734-9. [Abstract] [Full-text]
44. Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin.
    Mol Biol Cell, 18(10): 4143-54. [Abstract] [Full-text]
45. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Oncogene, 26(44): 6386-95. [Abstract] [Full-text]
46. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Virchows Arch, 451(4): 743-9. [Abstract] [Full-text]
47. Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile.
    Invest New Drugs, 25(6): 525-33. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.